CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update

CytomX Therapeutics (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today reported full-year 2017 financial results and provided an operational update on the company.

As quoted in the press release:

“The CytomX team continued tremendous execution during 2017, driving our transition to a clinical-stage company with the initiation of Phase 1/2 studies for two wholly-owned and one partnered program,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics.

“During 2018, we expect initial data readouts from our PD-L1-targeting Probody therapeutic, CX-072, and our CD166-targeting Probody drug conjugate, CX-2009. We also expect to initiate clinical studies for two additional programs this year, resulting in five clinical-stage Probody therapeutic programs by year end. Our deepening pipeline of innovative therapeutics has the potential to make a meaningful difference in the lives of people with cancer,” continued Dr. McCarthy.

Click here to read the full press release.